Davis Maris

The past year has been a rollercoaster ride for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) and its investors. But even with the stock down 48.6 percent in the past year, investors may have more downside ahead in 2018, according to Wells Fargo.  The Analyst Wells Fargo analyst...

Biotech traders are always on the lookout for stocks with major catalysts on the horizon, and newly-public Kala Pharmaceuticals Inc (NASDAQ: KALA) fits the mold ahead of what will be a critical second half of 2017 for the company. On Monday, Wedbush analyst Liana Moussatos highlighted two key...